



July 15, 2015

Gene Techno Science Co., Ltd.
Code: 4584 (TSE Mothers)
President
Masanari Kawaminami

Announcement of acquisition of Shares of Gene Techno Science by Dydo Drinco, Inc.

Gene Techno Science Co., Ltd. (“GTS”) announced the transfer of its shares to Dydo Drinco, Inc. (Code: 2590 TSE 1st section. “Dydo”) from Whiz Healthcare PE1 Limited Partnership (“Whiz Healthcare”), which is the largest shareholder of GTS, as this will result in a change of large shareholders.

1. Background of transaction

GTS had developed Filgrastim biosimilar (“Product”) which was launched in May 2013 by a pharmaceutical company which co-developed the Product with GTS and obtained the Japanese manufacture and marketing approval of the Product. GTS intends to be the pioneer in the field of biosimilar business and is continuously and actively undertaking research and development of biosimilars.

Whiz Partners Inc. (“Whiz Partners”) is the unlimited partner of Whiz Healthcare, which entered into an Investment Agreement with GTS in February 2013 and has fully supported GTS in business development, alliance activities and so on for the purpose of increasing the value of GTS.

Dydo, which holds high confidence in society, is a leading company in the field of beverage and also moves into, including without limitation, in the pharmaceutical industry through its group company. Further, Dydo searches for opportunities of new business development.

Under the circumstance, Whiz Partners discussed with Dydo and GTS an investment arrangement and Dydo agreed to obtain a certain number of shares of GTS from Whiz Healthcare. GTS also welcomes the arrangement expecting exchange of information and advises in the pharmaceutical industry between Dydo and GTS, which will be beneficial for business of each of the two companies.

2. Transaction details

Whiz Healthcare will assign to Dydo 100,000 shares of GTS from 225,105 shares of GTS in the possession of Whiz Healthcare as of July 21, 2015, and therefore, Dydo will become the 2nd largest shareholder of GTS. Whiz Healthcare will exercise its 9 stock acquisition rights (95,337 shares) of the 2nd Stock Acquisition Rights issued on May 1, 2013 in order to maintain its rate of share of GTS occupied by Whiz Healthcare.

GTS will receive 179,996,000 Japanese Yen in return, and plans to spend it for the research and development of GTS's biosimilar pipeline.

3. Change in Shareholders listing

Before transaction		After transaction	
Whiz Healthcare	9.36%	Whiz Healthcare	8.81%
Yuuichi Kakinuma	4.16%	Dydo Dorinco	4.00%
SBI Securities Co., Ltd.	3.15%	Yuuichi Kakinuma	4.00%

4. Others

There is almost no influence of this transaction expected on GTS's performance. In the event that Dydo and GTS agree on any alliance in the pharmaceutical industry and so on in the future, such progress will be informed as soon as possible.

Media Contact:

E-mail: info@g-gts.com

Masaki Okusawa

Tel: 81-3-3517 1353